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Abstract
IMPORTANCE—Out-of-hospital cardiac arrest (OHCA) occurs in more than 6000 children each
year in the United States, with survival rates of less than 10% and severe neurologic morbidity in
many survivors. Post–cardiac arrest hypotension can occur, but its frequency and association with
survival have not been well described during targeted temperature management.
OBJECTIVE—To determine whether hypotension is associated with survival to discharge in
children and adolescents after resuscitation from OHCA.

Author Manuscript

DESIGN, SETTING, AND PARTICIPANTS—This post hoc secondary analysis of the
Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) trial included 292 pediatric
patients older than 48 hours and younger than 18 years treated in 36 pediatric intensive care units
from September 1, 2009, through December 31, 2012. Participants underwent therapeutic
hypothermia (33.0°C) vs therapeutic normothermia (36.8°C) for 48 hours. All participants had
hourly systolic blood pressure measurements documented during the initial 6 hours of temperature
intervention. Hourly blood pressures beginning at the time of temperature intervention (time 0)
were normalized for age, sex, and height. Early hypotension was defined as a systolic blood
pressure less than the fifth percentile during the first 6 hours after temperature intervention. With
use of forward stepwise logistic regression, covariates of interest (age, sex, initial cardiac rhythm,
any preexisting condition, estimated duration of cardiopulmonary resuscitation [CPR], primary
cause of cardiac arrest, temperature intervention group, night or weekend cardiac arrest, witnessed
status, and bystander CPR) were evaluated in the final model. Data were analyzed from February
5, 2016, through June 13, 2017.

Author Manuscript

EXPOSURES—Hypotension.
MAIN OUTCOMES AND MEASURE—Survival to hospital discharge.
RESULTS—Of 292 children (194 boys [66.4%] and 98 girls [33.6%]; median age, 23.0 months
[interquartile range, 5.0–105.0 months]), 78 (26.7%) had at least 1 episode of early hypotension.
No difference was observed between the therapeutic hypothermia and therapeutic normothermia
groups in the prevalence of hypotension during induction and maintenance (73 of 153 [47.7%] vs
72 of 139 [51.8%]; P = .50) or rewarming (35 of 118 [29.7%] vs 19 of 95 [20.0%]; P = .10) during
the first 72 hours. Participants who had early hypotension were less likely to survive to hospital
discharge (20 of 78 [25.6%] vs 93 of 214 [43.5%]; adjusted odds ratio, 0.39; 95% CI, 0.20–0.74).

Author Manuscript

CONCLUSIONS AND RELEVANCE—In this post hoc secondary analysis of the THAPCA
trial, 26.7% of participants had hypotension within 6 hours after temperature intervention. Early
post–cardiac arrest hypotension was associated with lower odds of discharge survival, even after
adjusting for covariates of interest.
Out-of-hospital cardiac arrest (OHCA) occurs in more than 6000 children each year in the
United States, with survival rates of less than 10%.1,2 After initial resuscitation from OHCA
and admission to a pediatric intensive care unit, many children die in the post–cardiac arrest
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period before hospital discharge.3 Many survivors of pediatric OHCA sustain short- and
long-term neurologic morbidities.3–5
The post–cardiac arrest syndrome is characterized by myocardial dysfunction, a systemic
ischemia-reperfusion response, brain injury, and multiorgan dysfunction.6–8 A study of
children resuscitated from in-hospital cardiac arrest (IHCA) and OHCA showed that early
postresuscitation hypotension (within 6 hours after the return of spontaneous circulation
[ROSC]) is common and associated with increased odds of in-hospital mortality and
unfavorable neurologic outcome.9 Similarly, adult data suggest that early hypotension after
cardiac arrest is associated with higher mortality rates.10–12 In a secondary analysis of a
large randomized clinical trial of targeted temperature management (TTM) for adult OHCA,
lower mean arterial pressure and use of higher doses of vasopressors were associated with
increased mortality.13

Author Manuscript

The Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) trial, a recent large
randomized clinical trial comparing therapeutic hypothermia (33°C) with therapeutic
normothermia (36.8°C) for 48 hours after pediatric OHCA, did not show a difference in 1year neurobehavioral outcomes or mortality.4 In this post hoc secondary analysis, we aimed
to (1) evaluate the association of hypotension within 6 hours (early) and within 72 hours
after study intervention with survival to hospital discharge and (2) describe the association
of temperature intervention with blood pressure.

Methods

Author Manuscript

This study is a post hoc secondary analysis of data from the THAPCA trial.4 The trial
design, protocol, and results have been described previously.14–16 Enrollment of patients in
THAPCA was approved by the institutional review boards of all 36 sites. All patients’
parents or guardians provided written informed consent. This secondary analysis was
exempted by the institutional review board of the Children’s Hospital of Philadelphia.
THAPCA Study

Author Manuscript

The THAPCA trial17 was conducted from September 1, 2009, through December 31, 2012,
at 36 pediatric intensive care units in the United States and Canada.4 Children and
adolescents older than 48 hours and younger than 18 years who sustained an OHCA,
received more than 2 minutes of chest compressions, and were admitted to an intensive care
unit while intubated and receiving mechanical ventilation after ROSC were eligible for the
THAPCA trial. Major exclusion criteria consisted of the inability to randomize within 6
hours after ROSC and a Glasgow Coma Scale motor response score of less than 5 (range, 1–
6, with higher scores indicating a better motor response). The complete list of exclusion
criteria is included in the appendix of the original article.4 Participants were randomized 1:1
to therapeutic hypothermia or therapeutic normothermia within 6 hours after ROSC by using
permuted blocks stratified by age (<2, 2 to <12, or ≥12 years).
The TTM intervention was initiated as soon as possible after randomization and maintained
for 120 hours in the groups undergoing therapeutic hypothermia (33.0°C; range,
32.0°C-34.0°C) and therapeutic normothermia (36.8°C; range, 36.0°C-37.5°C) (Figure 1).
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Participants were sedated and pharmacologically paralyzed to achieve the target temperature
using external cooling blankets (Cincinnati Sub-Zero). Participants undergoing therapeutic
hypothermia underwent cooling to 33.0°C, maintenance at 32.0°C to 34.0°C for 48 hours,
and rewarming for approximately 16 to 24 hours to 36.8°C, which was actively maintained
through hour 120. Participants undergoing therapeutic normothermia had their core
temperature actively maintained at 36.8°C (range, 36.0°C-37.5°C) through 120 hours.

Author Manuscript

Per the THAPCA protocol, blood pressure was monitored by an arterial catheter. Blood
pressures were documented hourly during the induction, maintenance, and rewarming
phases. No explicit hemodynamic management protocol was used; however, protocol
training recommended that the clinical team maintain blood pressure in a normal range for
age and diagnosis, with accounting for preload, contractility, and afterload. The primary
outcome of the THAPCA trial was survival with a favorable neurologic outcome at 12
months.
Hypotension Study

Author Manuscript

All participants included in the THAPCA trial were eligible for the hypotension study.
Participants were excluded if they did not have the TTM intervention initiated. Hypotension
was defined as a systolic blood pressure (SBP) of less than the fifth percentile derived from
normative data for age, sex, and height.18 Hourly invasive arterial blood pressure
measurements were recorded during the first 72 hours of TTM intervention. Blood pressure
measurements from ROSC to initiation of the TTM intervention were not available. If a
measured height was not available, the 50th percentile for height and sex was used for
normalization. This procedure was followed for 28 participants. Our primary exposure
variable was at least 1 episode of hypotension during the first 6 hours after TTM
intervention (early hypotension) or from 0 to 72 hours (hypotension in the first 72 hours).
Hypotension burden was defined as the percentage of hypotensive measurements during
these periods.

Author Manuscript

Time 0 was defined as the time of initiation of the TTM intervention (Figure 1). Therefore,
the 0- to 6-hour blood pressure period occurred during therapeutic hypothermia induction or
during therapeutic hypothermia induction and maintenance. The 0- to 72-hour period
occurred during therapeutic hypothermia induction, maintenance (48 hours), rewarming
(≤24 hours), and part of normothermia. For participants undergoing therapeutic
normothermia, the corresponding periods from study intervention (time 0) were used.
Because of the variable time to achieve maintenance temperature, we compared hypotension
prevalence in the therapeutic normothermia and therapeutic hypothermia groups by the
combination of the induction and maintenance phases and by the rewarming phase.
Data collected in the THAPCA study included participant demographics, cardiac arrest
characteristics, and cardiac arrest care data after intervention initiation. Data from nights and
weekends were previously published.19 The number of vasoactive agents were counted from
the participant’s concomitant medication log and included epinephrine, phenylephrine,
norepinephrine, dobutamine, and dopamine. Vasopressin, milrinone, and corticosteroids
(hydrocortisone or methylprednisolone) were analyzed as yes or no. Indications for
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medication administration and the timing of initiation, dosing, titration, or discontinuation
within a 24-hour period were not documented.
Medications administered were documented by day from randomization (day 0), which
concluded at midnight of each day. Day of medication administration was aligned with
blood pressure period (0–6 hours or 0–72 hours) for each participant. If the participant’s
measurement period crossed 2 days, the higher number of vasoactive agents was used for
analysis. Description of vasoactive medications by phase (combined inductionmaintenanceandrewarming)couldnotbeperformed because of the variable time to achieve
maintenance phase.
Statistical Analysis

Author Manuscript

Data were analyzed from February 5, 2016, through June 13, 2017. Frequencies and
percentages or medians and interquar-tile ranges (IQRs) were used to summarize participant,
cardiac arrest, and post–cardiac arrest care characteristics. Univariate associations between
characteristics and the presence of hypotension were assessed using the Wilcoxon rank sum
test or the χ2 test of no association. A forward stepwise multivariate logistic regression
model was used to estimate the asso ciation between survival to hospital discharge and early
hypotension. A 2-sided P = .05 was used as the criterion for entering or leaving the model.
Other variables entered into the model as potential predictors included age, sex, initial
cardiac rhythm, primary cause of cardiac arrest, temperature treatment group, night or
weekend cardiac arrest, estimated duration of cardiopulmonary resuscitation (CPR),
preexisting condition, witnessed status, and bystander CPR. Estimated duration of CPR was
highly collinear with the number of epinephrine doses but had fewer missing data and
therefore was entered into the regression model. Lactate levels were not entered into the
model because of collinearity with hypotension and high levels of missingness during these
periods. The primary outcome was survival to hospital discharge.

Author Manuscript

Kaplan-Meier estimates of the time to death during the first year after cardiac arrest were
generated,and differences between the therapeutic hypothermia and therapeutic
normothermia groups were evaluated using the log-rank test. Analyses were completed
using SAS software (version 9.4; SAS Institute).

Results

Author Manuscript

Two hundred ninety-five individuals from the THAPCA trial were eligible. After applying
exclusion criteria, 292 participants underwent analysis (194 boys [66.4%] and 98 girls
[33.6%]; median age, 23.0 months [IQR, 5.0–105.0 months]); 3 were excluded because they
never received the TTM intervention. The median time from ROSC to TTM initiation was
5.8 hours (IQR, 5.1–6.5 hours). A description of the participant, cardiac arrest, and post–
cardiac arrest care characteristics by TTM intervention is found in the eTable in the
Supplement. We found no significant differences in demographics or cardiac arrest
characteristics between groups.
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Seventy-eight of 292 participants (26.7%) had at least 1 episode of hypotension during the
first 6 hours of temperature intervention. Participants who had hypotension were more likely
to have a preexisting condition, a cardiac cause of arrest, or a higher lactate level and to have
received more than 30 minutes of CPR and more than 4 doses of epinephrine (Table 1). We
found no difference in sex, race, cardiac arrest time of week, initial rhythm, witnessed status,
or time from ROSC to intervention. More participants with hypotension received at least 1
vasoactive agent, milrinone, or vasopressin, although 18 of 78 participants (23.1%) with
early hypotension received no vasoactive agents. We found no difference in the prevalence
of hypotension by TTM intervention.

Author Manuscript

Among the 78 participants with early hypotension, the median burden of hypotension per
participant was 31.0% of measurements (IQR, 16.7%−60.0%). Of participants with a burden
of hypotension of at least 16.7% of measurements, 9 of 49 (18.4%) did not receive a
vasoactive infusion.

Author Manuscript

One hundred thirteen participants (38.7%) survived to discharge. Participants who had early
hypotension (0–6 hours) had lower rates of survival to hospital discharge (Table 2). After
controlling for witnessed status, duration of CPR, and the presence of a preexisting
condition, early hypotension was associated with significantly decreased odds of survival to
discharge (adjusted odds ratio [AOR], 0.39; 95% CI, 0.20–0.74). Early hypotension burden
(0–6 hours) was also associated with significantly decreased odds of survival to discharge.
For each 10% increase in the number of hypotension measurements, a 20% decrease
occurred in the odds of survival (AOR, 0.80; 95% CI, 0.69–0.93). The probability of survival
over 1 year was significantly lower in participants with early hypotension (0–6 hours)
regardless of TTM arm (log-rank test of equality over strata, P < .001) (Figure 2A). No
interaction was found between TTM and blood pressure (P = .49).
0–72 Hours After TTM Intervention

Author Manuscript

One hundred sixty-one of 292 participants (55.1%) had hypo-tension during the first 72
hours of temperature intervention (Table 3). Among those with hypotension, the median
burden of hypotension per participant was 6.7% (IQR, 2.9%−18.8%) of measurements.
Hypotension was more common in participants with no bystander CPR, with preexisting
conditions, a cardiac cause of arrest, a witnessed cardiac arrest, and a higher post–cardiac
arrest lactate level and in older chil dren. We found no difference in sex, race, cardiac arrest
time of week, initial rhythm, duration of CPR, or time from ROSC to intervention.
Participants with hypotension were more likely to receive vasoactive infusions (122 of 161
[75.8%] vs 72 of 131 [55.0%]; P < .001) and corticosteroids (41 of 161 [25.5%] vs 16 of 131
[12.2%]; P = .004), although 39 of 161 with hypo-tension (24.2%) did not receive a
vasoactive infusion. We found no difference in the prevalence of any hypotension by TTM
intervention or in survival to discharge by blood pressure group (Table 2) and no difference
in the probability of survival over 1 year by blood pressure group in the first 72 hours
regardless of TTM arm (P = .10) (Figure 2B).
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One hundred forty-five of 292 participants (49.7%) had hypotension during the combined
induction and maintenance phase (≤48 hours for a median of ±2.8 hours from initiation of
TTM intervention), including 73 of 153 participants undergoing therapeutic hypothermia
(47.7%) and 72 of 139 undergoing therapeutic normothermia (51.8%) (P = .50). Fifty-four
of 213 participants (25.4%) had hypotension during the rewarming period, including 35 of
118 participants undergoing therapeutic hypothermia (29.7%) and 19 of 95 undergoing
therapeutic normothermia (20.0%) (P = .10) (eTable in the Supplement).

Author Manuscript

No difference between therapeutic normothermia and hypothermia groups occurred in the
number of participants who received vasoactive infusions or vasopressin during day 0 or 1;
however, fewer participants in the therapeutic normothermia group received a vasoactive
agent on day 2 (42 of 112 [37.5%] vs 69 of 134 [51.5%]) or 3 (36 of 102 [35.3%] vs 65 of
125 [52.0%]) compared with the therapeutic hypothermia group. A larger percentage of
participants undergoing therapeutic normothermia received vasopressin on day 1 only (30 of
131 [22.9%] vs 23 of 152 [15.1%]) and received more corticosteroids on every day (eTable
in the Supplement).

Discussion

Author Manuscript

In this secondary analysis of the THAPCA trial, early hypotension within 6 hours after TTM
intervention occurred in approximately one-quarter of participants and was associated with
decreased survival to hospital discharge. Furthermore, participants who had a higher
hypotension burden were less likely to survive to discharge, a finding supporting a doseresponse effect. In contrast, hypotension during the first 72 hours of TTM intervention was
not associated with outcome, suggesting less vulnerability to hypotensive episodes during
later periods after cardiac arrest in the THAPCA trial.

Author Manuscript

In the present study, we applied previously published definitions of hypotension (SBP <5th
percentile for age and sex) and found the prevalence of hypotension in the first 6 hours after
intervention initiation (approximately 6–12 hours after ROSC) to be lower than the 56%
described in 0 to 6 hours after ROSC in a pediatric IHCA and OHCA cohort.9 Adult
studies10,11 report early hypotension prevalence rates in combined IHCA and OHCA cohorts
of 47% to 65%. Hypo-tension is common after cardiac arrest and is caused by a combination
of ischemia and reperfusion and myocardial dysfunction.6,20 The lower rate of hypotension
in the present cohort suggests that secular improvements in post-cardiac arrest care may
have been associated with decreased prevalence of post–cardiac arrest hypotension. Other
possible reasons to explain the lower rate in the present cohort may be that (1) research
training and monitoring in an intervention trial encouraged hypotension prevention; (2) a
Hawthorne effect may have occurred for a consented cohort of a randomized clinical trial;
(3) the 0- to 6-hour period in this cohort was approximately 6 to 12 hours after ROSC, not 0
to 6 hours after ROSC; and (4) lack of participants with IHCA may have reduced higher
rates of hypotension based on preexisting illnesses.
We also evaluated the hypotension burden during both periods and found a dose-response
effect. Similarly, Kilgannon et al12 demonstrated a dose-response effect after adult cardiac
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arrest by using a different method. Hypotension burden quantifies a “dose” of hypotension
per participant accounting for time and severity, not just presence or absence. We selected
SBP a priori because of the availability of normative data and previously published pediatric
literature.9

Author Manuscript

In our cohort, fewer participants with early hypotension survived to discharge. Furthermore,
we found that as the number of measurements of hypotension increased, the odds of
discharge survival decreased. This finding supports previous findings in a combined IHCA
and OHCA cohort of 383 children9 that early systolic hypotension was associated with
worse outcomes. In that study,9 early systolic hypotension was associated with higher rates
of in-hospital mortality and worse hospital discharge neurologic outcomes. Similarly, Lin et
al21 found that hypotension within 1 hour from ROSC after pediatric OHCA was associated
with lower rates of discharge survival. Despite the consistency of these findings, whether
early postresuscitation hypotension causes worse outcomes or is a marker of more severe
cardiac arrest, including prolonged CPR requiring more doses of epinephrine and higher
post–cardiac arrest lactate levels, remains unclear. Although these significant differences
were observed in the early hypotension group, no difference was found between hypotension
groups in the 0- to 72-hour analysis despite hypotension being more prevalent. These
findings may be attributed to early hypotension being a bio-marker of injury severity, thus
leading to death, or early hypotension occurring at an especially vulnerable time for the
brain and/or heart, suggesting that improvement in blood pressure may result in more
favorable outcomes.

Author Manuscript

These data support the American Heart Association recommendations22 that parenteral
fluids and/or inotropes or vasoactive drugs be used to maintain an SBP greater than the fifth
percentile for age. In our study, 163 of 292 participants (55.8%) were treated with at least 1
vasoactive infusion in the first 6 hours after temperature intervention, including 60 of 78
with early hypotension (76.9%) and 103 of 214 without early hypotension (48.1%). In
contrast, in the previous study of early post–cardiac arrest hypotension,9 only 41% of
participants with hypotension received at least 1 vasopressor compared with 23% without
hypotension. This notable increase in the use of vasoactive infusions suggests a change in
practice between the 2003–2004 observational cohort in that earlier study9 and the later
period when the THAPCA trial was performed. In the THAPCA trial, blood pressure targets
and management were not protocolized, but research training included guidelines targeting
normal blood pressure for age. Although determining whether the increase in the use of
vasoactive infusions has changed outcomes during the past decade is not possible, these data
suggest that protocols with criteria for post–cardiac arrest care may drive clinicians’
management and thus could affect outcomes in the longer term.

Author Manuscript

Hypotension occurred in 49.7% of participants during the combined induction-maintenance
phase and 25.4% during the rewarming phase; however, no difference was found between
therapeutic hypothermia and therapeutic normothermia groups. Hypotension during
rewarming was described in a trial of therapeutic hypothermia for pediatric traumatic brain
injury23,24 and was more common during the rewarming period and in patients who received
the therapy. Rewarming is a vulnerable time when vasodilation occurs because the post–
cardiac arrest syndrome has often not resolved. Compared with the traumatic brain injury
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trial,23,24 the THAPCA trial had later rewarming at more than 48 hours after acute injury,
different definitions of hypotension, and different underlying pathophysiologic features. The
THAPCA investigators specifically encouraged hypotension prevention because of the
known hypotension during rewarming in the traumatic brain injury trial.23,24
A post hoc analysis from the adult TTM trial comparing 33°C with 36°C for 24 hours after
OHCA demonstrated that blood pressures did not differ between treatment arms until
rewarming, at which point participants in the therapeutic hypothermia arm had lower mean
arterial pressures.13 These findings differed from those of our study, in which during
rewarming, 29.7% of participants receiving therapeutic hypothermia had hypotension vs
20.0% of participants receiving therapeutic normothermia. This finding may be attributable
to rewarming beginning approximately 24 hours later in the THAPCA trial and thus later
after ROSC, with more time for post–cardiac arrest syndrome to resolve.

Author Manuscript

Limitations

Author Manuscript

Our study has several limitations. First, this study was a secondary analysis of a randomized
clinical trial of TTM of a severely injured pediatric population with OHCA and therefore
represents a subset of the population with OHCA and may not be generalizable to all
survivors of OHCA who are admitted to a pediatric intensive care unit. Second, blood
pressure data were not collected from ROSC to the intervention–approximately the first 6
hours after ROSC–a potentially important time when blood pressure and treatment may
affect outcomes. Third, vasoactive medication infusion dosing and timing were not available,
and our data are limited to ordered medications rather than medications confirmed to be
administered. Fourth, the timing of induction and rewarming were variable, and therefore
matching specific periods was challenging. Fifth, echocardiogram data were not available to
characterize myocardial function. Sixth, this observational study from a randomized clinical
trial cannot determine cause and effect. Finally, we evaluated the association of SBP with
discharge mortality but not diastolic or mean blood pressures.

Conclusions
In this secondary analysis of the THAPCA trial, 26.7% of participants had hypotension
within 6 hours of the study intervention. Early post–cardiac arrest hypotension and the
burden of early hypotension were associated with lower odds of survival to discharge, even
after adjusting for covariates of interest.

Supplementary Material
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Key Points
Question
Is hypotension after resuscitation from pediatric out-of-hospital cardiac arrest associated
with lower rates of survival to discharge in children treated with targeted temperature
management?
Findings

Author Manuscript

In this post hoc secondary analysis of a randomized clinical trial that included 292
children and adolescents treated with therapeutic hypothermia after pediatric cardiac
arrest, 78 (26.7%) had at least 1 episode of hypotension in the first 6 hours after
temperature intervention. Postarrest hypotension was associated with lower odds of
surviving to discharge.
Meaning
Hypotension early after pediatric out-of-hospital cardiac arrest is common and associated
with lower odds of survival to discharge.
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Figure 1. Time Frame for Interventions After Out-of-Hospital Cardiac Arrest (OHCA)

Author Manuscript

A indicates the early (6-hour) blood pressure period from study intervention initiation; B,
the 72-hour period from study intervention initiation; C, the period of induction to achieve
hypothermia (HT); D, the period of maintenance at goal temperature; and E, the period of
rewarming from HT back to normothermia (NT). ROSC indicates return of spontaneous
circulation.
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Figure 2. Kaplan-Meier Survival Curves

Early hypotension indicates 0 to 6 hours after initiation of target temperature maintenance
(TTM) treatment; hypotension, 0 to 72 hours after initiation of TTM treatment. The TTM
arms consist of hypothermia (HT) and normothermia (NT), described in detail in the
THAPCA Study subsection of the Methods section. Tick marks indicate censorship.

Author Manuscript
JAMA Pediatr. Author manuscript; available in PMC 2018 November 05.

a

Author Manuscript

Author Manuscript
174 (59.6)
53 (18.2)

White

Other or unknown

214(73.3)
13 (4.5)

Not Hispanic or Latino

Unknown

JAMA Pediatr. Author manuscript; available in PMC 2018 November 05.
66 (22.6)
35 (12.0)
41 (14.0)
49 (16.8)
71 (24.3)

Lung or airway disease

Congenital heart disease

Gastrointestinal tract

Neurologic

Other
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Initial cardiac arrest rhythm noted by EMS or hospital, No. (%)
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15 (19.2)
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Yes (n = 78)

Any Hypotension at 0–6 h
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Patient and Cardiac Arrest Characteristics by Hypotension Group

c

c
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.38

c

.06

c
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c

.46

c
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c

.52
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c
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c
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c
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P Value
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>15to≤30min
>30min
Unable to determine

Author Manuscript

JAMA Pediatr. Author manuscript; available in PMC 2018 November 05.
40 (13.7)
41 (14.0)
76 (26.0)
30 (10.3)

2
3
4
>4
Missing

153 (52.4)
139 (47.6)

Hypothermia
Normothermia

Treatment received, No. (%)

5.8 (5.1–6.5) [292]

51 (17.5)

1

Time from ROSC to TTM initiation, median (IQR), h [No. of participants]

19 (6.5)
35 (12.0)

0

Total No. of doses of epinephrine administered by EMS and at hospital, No. (%)

66 (22.6)

≤15 min

Estimated duration of chest compressions, No. (%)

183 (62.7)

Bystander chest compressions, No. (%)

34(11.6)

Unknown
108 (37.0)

10 (3.4)

Other

Cardiac arrest witnessed, No. (%)

211(72.3)

Respiratory

Cardiac

37(12.7)

23 (7.9)

Ventricular fibrillation or tachycardia

Primary cause of cardiac arrest, No. (%)

42 (14.4)

PEA

Overall (N = 292)
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Characteristic
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115 (53.7)
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24(11.2)
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c
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3.7 (1.8–6.7) [238]

Minimum measured lactate level, median (IQR), mmol/L [No. of participants]

42 (14.4)

Vasopressin administered, No. (%)

25(11.7)

18 (8.4)

16 (7.5)

5 (2.3)

38 (17.8)

60 (28.0)
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7.5 (4.2–11.5) [67]

31.0 (16.7–60.0) [78]
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c
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c
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b

<.001

b

<.001

b

P Value

Calculated using the Wilcoxon rank sum test.

Calculated using the χ2 test of no association.

c

b

a
Indicates hypotension at 0 to 6 hours. Percentages have been rounded and may not total 100.

Abbreviations: EMS, emergency medical services; IQR, interquartile range; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation; TTM, targeted temperature management.
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3

Corticosteroids administered. No. (%)
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2
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1

Milrinone administered, No. (%)
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0

No. of vasoactive agents administered, No. (%)
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4.7 (2.5–7.8) [238]

Maximum measured lactate level, median (IQR), mmol/L [No. of participants]

No medications, No. (%)

0.0 (0.0–13.4) [292]
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Initial cardiac arrest rhythm noted by EMS or hospital
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20(17.7)
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b
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.001

b

b
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b
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P Value
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OR(95%CI)

0.57 (0.30–1.10)
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7 (3.9)

92 (51.4)
77 (43.0)
91 (50.8)

Preexisting condition
Night or weekend arrest

50 (44.2)

65(57.5)

47 (41.6)

66 (58.4)

9 (8.0)

5 (4.4)

77 (68.1)

22(19.5)

4 (3.5)
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0.77 (0.48–1.23)

b
.27

.02

1.79(1.11–2.89)

0.67 (0.42–1.08)

1 [Reference]

0.25 (0.09–0.67)

0.68(0.17–2.77)

0.39 (0.19–0.80)

1 [Reference]

0.42 (0.11–1.58)

0.20 (0.10–0.40)

Unadjusted

b

b

.10

b

.02

P Value

OR(95%CI)

NA

1.75 (1.01–3.04)

NA

NA

NA

NA

NA

NA

0.57(0.14–2.27)

0.21 (0.10–0.42)

Adjusted

c
Calculated using the Wilcoxon rank sum test.

Calculated using the χ2 test of no association.

b

a
Percentages have been rounded and may not total 100. All variables were considered for entry into logistic regression model using forward stepwise selection.

Abbreviations: EMS, emergency medical services; IQR, interquartile range; NA, not applicable; OR, odds ratio; PEA, pulseless electrical activity.
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Normothermia

25 (14.0)

Hypothermia

Treatment received

Unknown

5(2.8)

134 (74.9)

Respiratory
Other
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Cardiac

Primary cause of cardiac arrest
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a
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66 (22.6)
35 (12.0)
41 (14.0)
49 (16.8)
71 (24.3)

Lung or airway disease

Congenital heart disease

Gastrointestinal tract

Neurologic

Other

172 (58.9)
19 (6.5)

Asystole

Bradycardia

Initial cardiac arrest rhythm noted by EMS or hospital, No. (%)

141 (48.3)

36 (12.3)

Prenatal

Night or weekend arrest, No. (%)

150 (51.4)

None

Preexisting chronic conditions, No. (%)

65 (22.3)

Hispanic or Latino

Ethnicity, No. (%)

65 (22.3)

Black or African American

Race, No. (%)
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109 (67.7)

25.0(5.0–146.0)

Yes (n = 161)

Any Hypotension at 0–72 h

c
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c
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Treatment received, No. (%)

5.8 (5.1–6.5) [292]

51 (17.5)

1

Time from ROSC to TTM initiation, median (IQR), h [No. of participants]

19 (6.5)
35 (12.0)

0

Total No. of doses of epinephrine administered by EMS and at hospital, No. (%)

66 (22.6)

≤15 min

Estimated duration of chest compressions, No. (%)

183 (62.7)

Chest compressions administered by bystander, No. (%)

34 (11.6)

Unknown
108 (37.0)

10 (3.4)

Other

Cardiac arrest witnessed, No. (%)

211 (72.3)

Respiratory

Cardiac
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Primary cause of cardiac arrest, No. (%)

42 (14.4)
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P Value
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1.2 (0.8–2.1) [285]

Minimum measured lactate level, median (IQR), mmol/L [No. of participants]

68 (23.3)

Vasopressin administered, No. (%)

26 (19.8)

16(12.2)

11 (8.4)

6 (4.6)

28 (21.4)

38 (29.0)

59 (45.0)

50 (38.2)

1.2 (0.8–1.7) [128]

3.9(1.9–6.1) [128]

0.0 (0.0–0.0) [131]

No (n = 131)

42 (26.1)

41 (25.5)

25 (15.5)

11 (6.8)

72 (44.7)

39 (24.2)

39 (24.2)

28 (17.4)

1.2 (0.8–2.6) [157]

5.3 (2.8–9.0) [157]

6.7 (2.9–18.8) [161]

Yes (n = 161)

c

.21

c

.004

c

c
.07

c
<.001

<.001

.16

c

<.001

b

<.001

b

P Value

Calculated using the Wilcoxon rank sum test.

Calculated using the χ2 test of no association.

c

b

a
Indicates hypotension at 0 to 72 hours. Percentages have been rounded and may not total 100.

Abbreviations: EMS, emergency medical services; IQR, interquartile range; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation; TTM, targeted temperature management.

57(19.5)

17 (5.8)

3

Corticosteroids administered. No. (%)

100 (34.2)

2

36 (12.3)

77 (26.4)

1

Milrinone administered, No. (%)

98 (33.6)

0

No. of vasoactive agents administered, No. (%)

78 (26.7)

4.4 (2.3–7.7) [285]

Maximum measured lactate level, median (IQR), mmol/L [No. of participants]

No medications, No. (%)

(292)1.4 (0.0–7.8)

Author Manuscript

Burden of hypotension, median (IQR), % [No. of participants]

Author Manuscript
Overall (N = 292)

Author Manuscript

Characteristic

Author Manuscript

Any Hypotension at 0–72 h
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